Medical News

RSS

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile)

30 Jun 2014

Complete analysis of regenerative medicine market

According to a new market research report by Allied Market Research titled, "GlobalRegenerative MedicineMarket (Technology, Applications, Geography) - Industry Analysis, Trends, Opportunities and Forecast, 2013-2020", the global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% during forecast period (2014 - 2020).

30 Jun 2014

Glenridge HealthCare Solutions acquired by WhiteGlove Health

WhiteGlove Health, Inc., a leading chronic care and population health management provider, announced the acquisition of Glenridge HealthCare Solutions, a premier provider of technology-enabled network development and consulting services.

30 Jun 2014

Lombard Medical exhibits Aorfix system at Critical Issues in Aortic Endografting symposium

Lombard Medical, Inc, a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAA), exhibited its Aorfix Endovascular stent graft system at the 18th international experts' symposium, Critical Issues in Aortic Endografting, in Malmö, Sweden on June 27-28, 2014.

30 Jun 2014

AMSURG offers $880M aggregate principal amount of senior unsecured notes due 2022

AMSURG Corp. today announced that it has launched its offering of approximately $880 million aggregate principal amount of senior unsecured notes due 2022 (the "Notes").

30 Jun 2014

Affimed Therapeutics files Form F-1 registration statement for public offering of common stock

Affimed Therapeutics today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common shares.

30 Jun 2014

Switching off a single gene converts human gastrointestinal cells into insulin-producing cells

By switching off a single gene, scientists at Columbia University's Naomi Berrie Diabetes Center have converted human gastrointestinal cells into insulin-producing cells, demonstrating in principle that a drug could retrain cells inside a person's GI tract to produce insulin.

30 Jun 2014

Higher risk of psychiatric disorders found in children born to women with fertility problems

Children born to women with fertility problems have a higher risk of psychiatric disorders than naturally conceived children. The increase in risk was described as "modest" by researchers from Denmark, but was found to persist throughout childhood and into young adulthood.

30 Jun 2014

Quantum Materials secures anti-counterfeiting quantum dot detection technology

Quantum Materials Corporation (OTCQB:QTMM) announces securing 3D printing and additive manufacturing anti-counterfeiting quantum dot detection technology developed at the Institute for Critical Technology and Applied Science and the Design, Research, and Education for Additive Manufacturing Systems (DREAMS) Laboratory at Virginia Tech.

30 Jun 2014

Sedia Biosciences to present results of HIV incidence assay at International AIDS Conference

Sedia Biosciences Corporation of Portland, Oregon will be presenting its first public results of a new rapid point-of-care HIV incidence assay at the upcoming 20th International AIDS Conference in Melbourne, Australia, July 21-25, 2014.

30 Jun 2014

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company's investigational anti-PD-1 antibody, for the treatment of advanced melanoma.

30 Jun 2014

MagForce publishes operative highlights and financial results for fiscal year 2013

MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results for the fiscal year ending on December 31, 2013 and operative highlights.

30 Jun 2014

Bacteria can survive under antibiotic exposure by developing a biological timer

Hebrew University of Jerusalem researchers showed that when exposed to repeated cycles of antibiotics, bacteria evolved a new adaptation by remaining dormant for the treatment period. The results show for the first time that bacteria can develop a biological timer to survive under antibiotic exposure.

30 Jun 2014

IXICO and VirtualScopics jointly lease office space in New Hope, Pennsylvania

VirtualScopics, Inc., a leading provider of clinical trial imaging solutions, and IXICO plc (AIM: IXI), the brain health company, announced today they are jointly leasing 2,190 sq. ft. of office space in New Hope, Pennsylvania, strategically located within the big pharma corridor that runs through New Jersey and Pennsylvania.

30 Jun 2014

FDA grants Thermedx 510(k) clearance for optional fluid warming in arthroscopic, hysteroscopic procedures

Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.

30 Jun 2014

Genervon generates biomarker data for its Phase 2a clinical trial for ALS

Genervon Biopharmaceuticals LLC ("Genervon") today announced that it has analyzed and generated a Biomarker Data Report for its recent Phase 2a clinical trial for ALS disease modification.

30 Jun 2014

Conventional fertility hormones do not increase risk of breast, gynecological cancers

There is "little evidence" that the use of conventional fertility hormones used for ovarian stimulation in the treatment of infertility increases the long-term risk of breast and gynecological cancers, according to the results of a substantial 30-year follow-up study.

30 Jun 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

First Edition: June 30, 2014

Today's early morning highlights from the major news organizations, including an announcement coming today for a new VA secretary and expectations for a Supreme Court decision on the challenge to the health law's contraceptive mandate by two for-profit companies.

30 Jun 2014

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

ALS stands for Amyotrophic Lateral Sclerosis, better known as “Lou Gehrig’s Disease”. It is a progressive neurodegenerative disease characterized by the death of motor neurons in the brain and spinal cord.

30 Jun 2014

Medical News

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Complete analysis of regenerative medicine market

Glenridge HealthCare Solutions acquired by WhiteGlove Health

Lombard Medical exhibits Aorfix system at Critical Issues in Aortic Endografting symposium

AMSURG offers $880M aggregate principal amount of senior unsecured notes due 2022

Affimed Therapeutics files Form F-1 registration statement for public offering of common stock

Switching off a single gene converts human gastrointestinal cells into insulin-producing cells

Higher risk of psychiatric disorders found in children born to women with fertility problems

Quantum Materials secures anti-counterfeiting quantum dot detection technology

Sedia Biosciences to present results of HIV incidence assay at International AIDS Conference

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

MagForce publishes operative highlights and financial results for fiscal year 2013

Bacteria can survive under antibiotic exposure by developing a biological timer

IXICO and VirtualScopics jointly lease office space in New Hope, Pennsylvania

FDA grants Thermedx 510(k) clearance for optional fluid warming in arthroscopic, hysteroscopic procedures

Genervon generates biomarker data for its Phase 2a clinical trial for ALS

Conventional fertility hormones do not increase risk of breast, gynecological cancers

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

First Edition: June 30, 2014

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

Membrane proteins in focus: Turning high-risk targets into routine workflows

How metabolic phenotyping can detect viral infections in minutes

Directed enzyme evolution and the Nobel Prize: Making enzymes evolve in the lab

Latest News